[Medical treatment for cardiomyopathies].
Newer drug therapy for patients with cardiomyopathies has been introduced with standard one. Beta-blocker therapy improves the prognosis in patients with ischemic and non-ischemic DCM and even in asymptomatic ones with LV dysfunction. The combined therapy of ACE inhibitor and angiotensin II receptor blocker, the intermittent intravenous infusion of inotropic agents and the supplement of phosphodiesterase inhibitor on induction of beta-blocker therapy also elucidate the effectiveness in DCM patients.
Suwa
M
M
3rd Div. Int. Med., Osaka Medical College.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000638:Amiodarone / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy*; D002312:Cardiomyopathy, Hypertrophic / Q000188:drug therapy*; D002316:Cardiotonic Agents / Q000627:therapeutic use; D006801:Humans; D017202:Myocardial Ischemia / Q000188:drug therapy
D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D002316:Cardiotonic Agents; D000638:Amiodarone